The Next Big Weight-Loss Shot is Already Available Online

An experimental weight-loss drug expected to move toward FDA approval is already being sold online, raising new questions about enforcement, patient safety and the fast-moving market for GLP-1 therapies.

What you’ll learn

• How sellers are marketing retatrutide before FDA approval
• Why the online peptide market is challenging FDA oversight
• What the issue could mean for regulators, manufacturers and health care stakeholders

Why this matters

Demand for weight-loss drugs is testing the boundaries of regulation, commercialization and online health care markets. POLITICO Pro helps health care organizations track how emerging products, enforcement gaps and stakeholder pressure could shape strategy, risk and policy planning.

Fill out the form to read the full POLITICO Pro article.